DermaSensor, a pocket-sized AI skin cancer detector, has been released

The DermaSensor device — the first artificial intelligence-based tester capable of detecting three common types of skin cancer in real time, has entered mainstream use in the US. The device has already been approved in the US for widespread use as a medical device.

The device has already received approval in the US for widespread use as a medical device.

DermaSensor uses elastic photon scattering (ESS) technology to analyze changes in the dermis. This technology measures how photons scatter as they interact with different cellular structures. Malignant skin tumors have differences in cellular and subcellular composition compared to benign tumors, resulting in differences in light scattering. Artificial intelligence analyzes spectroscopic images, identifies these differences, and provides information to physicians that helps assess the extent of cellular damage.

Artificial intelligence analyzes spectroscopic images, identifies these differences, and provides information to physicians that helps assess the extent of cellular damage.

The most common skin cancers are considered basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and melanoma, the most dangerous form of skin cancer because of its propensity to spread. DermaSensor demonstrated accuracy for melanoma at 87.5%, 97.8% for BCC and 98.7% for PCC, while the subjective judgment of primary care physicians averaged 83.0% accuracy. DermaSensor has also been found to reduce missed skin cancer cases from 18% to 9%.

The DermaSensor has also been shown to reduce missed skin cancer cases from 18% to 9%.